急性重複性癲癇發作市場機會、成長動力、產業趨勢分析與預測 2024 - 2032

Acute Repetitive Seizures Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032

出版日期: 2024年10月16日 | 出版商:

Global Market Insights Inc. | 英文 145 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2023 年，全球急性反覆發作市場規模達到 27 億美元，預計 2024-2032 年複合年成長率為 12.4%。這種成長主要歸因於癲癇發病率的上升和緊急治療方案的創新。鼻內製劑的最新進展顯著改變了市場格局。提供快速、非侵入性給藥的新療法越來越受歡迎，特別是在家庭護理環境中，可近性對於患者及其照護者來說至關重要。這些鼻內療法的易用性和快速作用加速了它們的採用，允許在沒有專業醫療監督的情況下立即進行干預。

急性重複性癲癇發作，也稱為癲癇叢集，是指在短時間內（通常為 24 至 48 小時）內發生一系列癲癇發作時發生的情況。這些發作可能會升級為癲癇持續狀態，這是一種可能危及生命的疾病。對於許多癲癇患者，尤其是那些難以控制癲癇發作的人來說，解決 ARS 至關重要。對有效治療方案日益成長的需求正在推動市場向前發展。

在產品分類方面，市場包括一系列解決方案，每種解決方案都能滿足患者的特定需求。主要細分市場之一的特點是其方便用戶使用和非侵入性的輸送方法，有利於快速吸收和快速控制癲癇發作——這是緊急情況下的一個重要因素。監管機構對某些治療方法的批准進一步提高了它們在醫療保健界的接受度和使用。在考慮分銷管道時，市場分為醫院藥房、零售藥房和線上平台。

市場範圍
開始年份	2023年
預測年份	2024-2032
起始值	27億美元
預測值	77 億美元
複合年成長率	12.4%

醫院藥房預計將顯著成長，預計複合年成長率為 12.2%。這一成長是由於與急性反覆癲癇發作相關的頻繁住院導致對有效癲癇治療藥物的需求增加。此外，這些藥局經常與專家密切合作，制定有效的癲癇治療方案，從而提高藥物的可近性和療效。北美急性重複性癲癇發作市場到 2023 年將達到 11 億美元，預計將以 12.3% 的複合年成長率成長。

該地區癲癇的高盛行率極大地影響了對有效治療方案的需求，而完善的醫療保健系統則支持及時診斷和介入。此外，大眾對癲癇的認知和教育的提高導致診斷更加頻繁，進一步推動市場成長。總體而言，隨著對有效、可及的治療方案的需求不斷增加，急性反覆癲癇發作市場有望取得重大進展。

The Global Acute Repetitive Seizures Market reached USD 2.7 billion in 2023 and is projected to experience 12.4% CAGR over 2024-2032. This growth is primarily attributed to the rising incidence of epilepsy and innovations in emergency treatment options. Recent advancements in intranasal formulations have notably transformed the market landscape. New therapies that offer rapid, non-invasive administration are becoming increasingly popular, especially in home care settings where accessibility is paramount for patients and their caregivers. The ease of use and quick action of these intranasal therapies have accelerated their adoption, allowing for immediate intervention without professional medical supervision.

Acute repetitive seizures, also referred to as seizure clusters, occur when a series of seizures transpire within a short period, typically 24 to 48 hours. These episodes can escalate into status epilepticus, a potentially life-threatening condition. For many individuals living with epilepsy, especially those who struggle to control their seizures, addressing ARS is critical. This growing need for effective treatment options is driving the market forward.

In terms of product classification, the market includes a range of solutions, each addressing the specific needs of patients. One of the leading segments is characterized by its user-friendly and non-invasive delivery method, which facilitates quick absorption and rapid seizure control-an essential factor during emergencies. The approval of certain treatments by regulatory bodies has further enhanced their acceptance and use within the healthcare community. When considering distribution channels, the market is segmented into hospital pharmacies, retail pharmacies, and online platforms.

Market Scope
Start Year	2023
Forecast Year	2024-2032
Start Value	$2.7 Billion
Forecast Value	$7.7 Billion
CAGR	12.4%

Hospital pharmacies are anticipated to see significant growth, with a projected CAGR of 12.2%. This increase is driven by the frequent hospital admissions related to acute repetitive seizures, leading to heightened demand for effective seizure management medications. Additionally, these pharmacies often work closely with specialists to create effective protocols for seizure treatment, thus improving both the accessibility and efficacy of the medications. North America acute repetitive seizures market reached USD 1.1 billion in 2023 and is expected to grow at an impressive CAGR of 12.3%.

The region's high prevalence of epilepsy significantly influences the demand for effective treatment options, while a well-established healthcare system supports timely diagnoses and interventions. Moreover, increased public awareness and education surrounding seizure disorders have resulted in more frequent diagnoses, further driving market growth. Overall, the acute repetitive seizures market is poised for significant advancements as the need for effective, accessible treatment options continues to rise.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Rising prevalence of epilepsy and seizure disorders
  - 3.2.1.2 Development of novel rescue medications
  - 3.2.1.3 Advances in non-invasive drug delivery systems
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Limited awareness and diagnosis
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Pipeline analysis
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 USL-261
5.3 Diastat Rectal Gel (DRG)
5.4 NRL-1
5.5 Other products

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Intranasal
6.3 Rectal
6.4 Oral
6.5 Other routes of administration

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Hospital pharmacies
7.3 Retail pharmacies
7.4 Online pharmacies

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE